BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32777714)

  • 1. Benefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer.
    Teufel A; Gerken M; Fürst A; Ebert M; Hohenthanner I; Klinkhammer-Schalke M
    Eur J Cancer; 2020 Sep; 137():148-160. PubMed ID: 32777714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer.
    Teufel A; Gerken M; Hartl J; Itzel T; Fichtner-Feigl S; Stroszczynski C; Schlitt HJ; Hofstädter F; Klinkhammer-Schalke M
    BMC Cancer; 2015 May; 15():419. PubMed ID: 25985893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal.
    Babcock BD; Aljehani MA; Jabo B; Choi AH; Morgan JW; Selleck MJ; Luca F; Raskin E; Reeves ME; Garberoglio CA; Lum SS; Senthil M
    Ann Surg Oncol; 2018 Jul; 25(7):1980-1985. PubMed ID: 29675762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system.
    Chen Y; Shankaran V; Hahn EE; Haupt EC; Bansal A
    J Manag Care Spec Pharm; 2023 Jun; 29(6):635-646. PubMed ID: 37276035
    [No Abstract]   [Full Text] [Related]  

  • 5. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
    Cascinu S; Poli D; Zaniboni A; Lonardi S; Labianca R; Sobrero A; Rosati G; Di Bartolomeo M; Scartozzi M; Zagonel V; Pella N; Banzi M; Torri V
    Eur J Cancer; 2019 Apr; 111():1-7. PubMed ID: 30797014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
    Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
    Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practice Variation in the Adjuvant Treatment of Colon Cancer in the Netherlands: A Population-based Study.
    Keikes L; Koopman M; Lemmens VEPP; VAN Oijen MGH; Punt CJA
    Anticancer Res; 2020 Aug; 40(8):4331-4341. PubMed ID: 32727761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
    Tournigand C; André T; Bonnetain F; Chibaudel B; Lledo G; Hickish T; Tabernero J; Boni C; Bachet JB; Teixeira L; de Gramont A
    J Clin Oncol; 2012 Sep; 30(27):3353-60. PubMed ID: 22915656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
    Ejaz A; Casadaban L; Maker AV
    J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.
    Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Muşină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
    J Clin Oncol; 2020 Nov; 38(31):3638-3651. PubMed ID: 32897827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and survival benefit of adjuvant chemotherapy in stage III colon cancer patients: Comparison of overall and age-stratified results by multivariable modeling and propensity score methodology in a population-based cohort.
    Hines RB; Bimali M; Johnson AM; Bayakly AR; Collins TC
    Cancer Epidemiol; 2016 Oct; 44():77-83. PubMed ID: 27513721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.
    Peng J; Li W; Zhang R; Lin J; Tang J; Wen Y; Lu Z; Wu X; Pan Z
    Cancer Commun (Lond); 2019 Oct; 39(1):59. PubMed ID: 31619288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Chemotherapy for Stage II Colon Cancer: Practice Patterns and Effectiveness in the General Population.
    Booth CM; Nanji S; Wei X; Peng Y; Biagi JJ; Hanna TP; Krzyzanowska MK; Mackillop WJ
    Clin Oncol (R Coll Radiol); 2017 Jan; 29(1):e29-e38. PubMed ID: 27663601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study.
    Kim KY; Cha IH; Ahn JB; Kim NK; Rha SY; Chung HC; Roh JK; Shin SJ
    J Surg Oncol; 2013 May; 107(6):613-8. PubMed ID: 23592499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor-stroma ratio in colon cancer.
    Polack M; Smit MA; van Pelt GW; Roodvoets AGH; Meershoek-Klein Kranenbarg E; Putter H; Gelderblom H; Crobach ASLP; Terpstra V; Petrushevska G; Gašljević G; Kjær-Frifeldt S; de Cuba EMV; Bulkmans NWJ; Vink GR; Al Dieri R; Tollenaar RAEM; van Krieken JHJM; Mesker WE;
    ESMO Open; 2024 Apr; 9(4):102988. PubMed ID: 38613913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
    Alwers E; Jansen L; Bläker H; Kloor M; Tagscherer KE; Roth W; Boakye D; Herpel E; Grüllich C; Chang-Claude J; Brenner H; Hoffmeister M
    Mol Oncol; 2020 Feb; 14(2):363-372. PubMed ID: 31816156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
    Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
    Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer.
    Bos AC; van Erning FN; van Gestel YR; Creemers GJ; Punt CJ; van Oijen MG; Lemmens VE
    Eur J Cancer; 2015 Nov; 51(17):2553-61. PubMed ID: 26360411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.